tirzepatide surmount-1 trial weight loss non-diabetic for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity GLP-1 drugs produce real weight

We provided an intention-to-treat analysis, where we compared the effect of being assigned to the treatment strategies at baseline, regardless of whether or not the individuals continued to follow the strategies during follow-up

Medication Check For at least 35 days before your appointment, we recommend stopping aspirin, ibuprofen (Advil, Motrin), naproxen, and other NSAIDs

Once weekly subcutaneous Month 3+ 1mg A higher dose level for patients who have completed the adjustment period

What to do when side effects will not go away For the 5 to 10% of people who experience persistent side effects beyond the typical adaptation period, there are several strategies worth discussing with a healthcare provider

Injecting into healthy skin reduces the chance of skin reactions and helps the medication work effectively, explains Dr

However, treatment discontinuation due to adverse events occurred in 24.6% and 3.9% of participants, respectively, mainly due to gastrointestinal adverse events